timothy sykes logo
SMMT Jumps As Summit Therapeutics Rides Ivonescimab Momentum Thumbnail
G Google News

SMMT Jumps As Summit Therapeutics Rides Ivonescimab Momentum

ELLIS HOBBS•UPDATED JUN. 14, 2026, 11:07 AM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Summit Therapeutics Inc. stocks have been trading up by 8.49 percent on strong sentiment around its latest clinical trial progress.

What Traders Need To Know

  • Ivonescimab plus chemotherapy showed a meaningful overall survival edge over tislelizumab combos in first-line squamous NSCLC, with Phase III HARMONi-6 data published in The Lancet and featured at ASCO.
  • ASCO Phase II data in metastatic colorectal cancer showed ivonescimab plus mFOLFOX6 delivered a 70.8% objective response rate versus historical bevacizumab+FOLFOX benchmarks.
  • A detailed HARMONi-6 readout showed ivonescimab cut risk of death by 34% in first-line advanced squamous NSCLC, with consistent PD-L1 subgroup benefit and no new safety issues.
  • A planned $500M equity raise, plus a $75M greenshoe, aims to fund ivonescimab and corporate needs, adding dilution risk even as it strengthens Summit Therapeutics Inc.’s cash runway.
  • Heavy insider buying by co-CEO Robert W. Duggan and COO/CFO Manmeet Singh Soni signals confidence, contrasting with a recent 10.2% pullback that sent SMMT down to $12.83.

Candlestick Chart

Weekly Update Jun 08 – Jun 12, 2026: On Sunday, June 14, 2026 Summit Therapeutics Inc. stock [NASDAQ: SMMT] is trending up by 8.49%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Summit Therapeutics is a late‑stage, single‑asset oncology developer with no commercial revenue, deeply negative profitability (ROE ~‑200%+; ROA ~‑230%+), and an extreme price‑to‑book of ~30x that embeds high approval and commercialization expectations for ivonescimab. Cash of ~$239M and a robust current ratio of 7.4 provide roughly 18–24 months of runway at the current ~$230M annualized operating loss, but free cash flow of ‑$93M in the latest quarter underscores heavy cash burn and persistent shareholder dilution risk.

Technically, SMMT remains in an intermediate‑term uptrend, consolidating after a sharp advance. This week’s range between ~$13.05 and ~$14.34, with closes skewed toward the upper half and a strong finish near $14.19, signals dip‑buying demand after the recent pullback to ~$13. The 5‑minute tape shows active intraday reversals around $13–13.20, confirming that zone as key support. For trading, $13.00 is a clear actionable support level; a decisive weekly close above $14.50 would reopen upside momentum.

Fundamentally, Summit’s outlook is exceptionally binary but currently favorable versus biotech benchmarks: positive Phase III OS benefit in squamous NSCLC (HARMONi‑6) and strong Phase II mCRC data position ivonescimab competitively versus standard PD‑1/VEGF strategies, justifying a valuation premium to typical pre‑revenue peers. The $500M equity raise is dilutive but extends runway into pivotal commercialization years and is counterbalanced by large insider buying from Duggan and senior management, signaling high conviction. With oncology catalysts (US BLA, additional data sets, conference visibility) ahead, I view risk‑reward as skewed positively and would anchor near‑term support at $13 and resistance at $18, targeting $20 over 12–18 months on successful regulatory progression.

More Breaking News

Quick Financial Overview

Summit Therapeutics Inc. is trading in a volatile but constructive band, with recent daily closes moving from $13.05 to $14.19 over a tight five-day window. Intraday, SMMT has printed a wide range, with a session that opened near $13, flushed to $12.92, and then ripped as high as $14.175 before closing around $14.01. That kind of intraday spread tells you this is a trader’s stock right now, driven by headlines and order flow rather than slow-moving fundamentals.

On the fundamentals side, Summit Therapeutics Inc. is still very much a clinical-stage, loss-making biotech. The latest quarterly report (period ending 2025/09/30) shows net income of about -$231.8M and EBITDA of roughly -$231.8M, with operating cash flow at about -$93.1M. Key ratios reflect that risk profile: return on equity is deeply negative, price-to-book is a rich 30.51, and cash flow per share is firmly in the red.

Balance sheet strength is the counterweight here. Cash and equivalents sit near $238.6M, with working capital around $181.5M and a current ratio of 7.4, while total debt is minimal, with long-term debt just under $2.8M and total debt-to-equity at 0.04. The planned $500M+ equity raise will likely extend that runway but also presses on per-share valuation, which traders must weigh against the upside implied by ivonescimab’s lung and colorectal cancer data.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading SMMT

Millionaire's
POV on SMMT

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”